According to differentiating syndrome and dividing patter, 41 cases of Facial Chloasma by Auricular Pressure in Shen (MA-AH), Fei (MA-IC 1), Neifenmi (MA-IC 3), Luanchao (MA-AT), Mianjia (MA-L) and Xia’erbei (MA-IC),...According to differentiating syndrome and dividing patter, 41 cases of Facial Chloasma by Auricular Pressure in Shen (MA-AH), Fei (MA-IC 1), Neifenmi (MA-IC 3), Luanchao (MA-AT), Mianjia (MA-L) and Xia’erbei (MA-IC), the total effective rate was 87.8%. Key Words Skin Pigmentation, Chloasma - Auricular Point Sticking - Syndrome Differ Treatment Author: Liu Guang-xia (1954-), female, associate professorTranslator: Xiao Yuan-chun展开更多
Background: Melasma and post-inflammatory hyperpigmentation provide a significant source of psychosocial morbidity, especially in those with Fitzpatrick skin types III-VI. In Europe, a proprietary product aimed at tre...Background: Melasma and post-inflammatory hyperpigmentation provide a significant source of psychosocial morbidity, especially in those with Fitzpatrick skin types III-VI. In Europe, a proprietary product aimed at treating these conditions, similar to Kligman’s formula but with a longer expiry date, has become available. Objectives: To assess patient satisfaction with a newly available combination de-pigmenting preparation. Methods: We conducted a small study to see if patients felt that this new product affected their quality of life and skin symptoms from hyperpigmentation. 41 subjects, who had all been prescribed a 15 g tube to use sparingly at night for 90 days within the last 12 months were telephoned to rate the effect the cream had on their quality of life and skin symptom improvement. Each patient also had their Dermatology Life Quality Index (DLQI) score assessed. Results: Out of the 29 patients who responded to the study, 22 had melasma and 7 had post-inflammatory hyperpigmentation from acne. 21 subjects felt that the cream made either a marked or moderate improvement on their quality of life and 23 subjects felt that the cream made either a marked or moderate improvement on their skin symptoms. Conclusion: Patients reported improvement in both hyperpigmentation and quality of life, suggesting a high level of satisfaction with treatment. The long shelf life of the product may also promote compliance and reduce health-care costs.展开更多
目的:观察外用3%氨甲环酸精华液治疗黄褐斑的疗效及不良反应。方法:将2021年6月-2021年12月在湘雅医院皮肤科就诊的50例黄褐斑患者按随机数字表法分为两组,实验组外用3%仙瑟氨甲环酸精华液+保湿霜,每日2次;对照组仅外用同种保湿霜,每日...目的:观察外用3%氨甲环酸精华液治疗黄褐斑的疗效及不良反应。方法:将2021年6月-2021年12月在湘雅医院皮肤科就诊的50例黄褐斑患者按随机数字表法分为两组,实验组外用3%仙瑟氨甲环酸精华液+保湿霜,每日2次;对照组仅外用同种保湿霜,每日2次。每4周回访1次,试验周期为8周,治疗8周停止治疗,随访至12周。回访时依据黄褐斑面积及严重程度评分(Melasma area severity index,MASI)评估疗效,并根据VISIA图评估实验组患者面部红斑改善程度。治疗12周回访时评估复发率、医生及患者满意率并记录不良反应。结果:治疗后4周、8周、12周,实验组的平均MASI均低于对照组,差异具有统计学意义(P<0.05),且实验组患者面部红斑改善情况均优于对照组。随着治疗时间的延长,实验组MASI逐步下降(P<0.05),患者面部红斑改善率逐渐升高。治疗12周回访时医生满意率为88%,患者满意率为92%。结论:外用氨甲环酸治疗黄褐斑疗效肯定,但是对于不同类型的黄褐斑,在起效时间、复发上可能存在不同。配方合理的复合制剂可能是氨甲环酸外用制剂的进一步研究方向。展开更多
目的:探讨光子嫩肤仪联合调Q激光治疗黄褐斑的近远期疗效。方法:选取2018年1月-2020年1月笔者科室确诊的118例女性黄褐斑患者,采用简单随机分组法分为观察组和对照组,每组59例。对照组采用调Q激光治疗,每月1次,共治疗6个月;观察组在对...目的:探讨光子嫩肤仪联合调Q激光治疗黄褐斑的近远期疗效。方法:选取2018年1月-2020年1月笔者科室确诊的118例女性黄褐斑患者,采用简单随机分组法分为观察组和对照组,每组59例。对照组采用调Q激光治疗,每月1次,共治疗6个月;观察组在对照组基础上联合光子嫩肤仪治疗,其中光子嫩肤使用频率为每2个月1次。对比两组患者的疗效,采用SOFT5.5皮肤检测仪对治疗前后皮肤性质进行检测,采用VISIA皮肤分析仪评估棕色斑特征计数,计算其下降率;对比治疗前后患者面部黄褐斑皮损面积与严重程度指数(Melasma area severity index,MASI)评分,记录两组治疗期间面部潮红、轻度水肿、灼痛感等不良反应发生情况;随访12个月,记录两组患者治疗后6个月、9个月、12个月的复发率。结果:治疗后,观察组有效率为96.61%,高于对照组的83.05%(P<0.05);治疗后,观察组色素斑、纹理、皱纹、毛孔及紫质评分均低于对照组(P<0.05);且观察组皮肤水分、弹性评分高于对照组,pH值、油脂评分低于对照组(P<0.05);治疗后,观察组棕色斑计数下降率显著高于对照组,观察组MASI评分显著低于对照组,差异均有统计学意义(P<0.05);治疗期间,两组不良反应发生率比较差异无统计学意义(P>0.05);随访12个月发现,观察组复发率显著低于对照组,差异有统计学意义(P<0.05)。结论:光子嫩肤仪联合调Q激光治疗黄褐斑疗效显著,皮损改善明显,复发率低,值得临床推广应用。展开更多
文摘According to differentiating syndrome and dividing patter, 41 cases of Facial Chloasma by Auricular Pressure in Shen (MA-AH), Fei (MA-IC 1), Neifenmi (MA-IC 3), Luanchao (MA-AT), Mianjia (MA-L) and Xia’erbei (MA-IC), the total effective rate was 87.8%. Key Words Skin Pigmentation, Chloasma - Auricular Point Sticking - Syndrome Differ Treatment Author: Liu Guang-xia (1954-), female, associate professorTranslator: Xiao Yuan-chun
文摘Background: Melasma and post-inflammatory hyperpigmentation provide a significant source of psychosocial morbidity, especially in those with Fitzpatrick skin types III-VI. In Europe, a proprietary product aimed at treating these conditions, similar to Kligman’s formula but with a longer expiry date, has become available. Objectives: To assess patient satisfaction with a newly available combination de-pigmenting preparation. Methods: We conducted a small study to see if patients felt that this new product affected their quality of life and skin symptoms from hyperpigmentation. 41 subjects, who had all been prescribed a 15 g tube to use sparingly at night for 90 days within the last 12 months were telephoned to rate the effect the cream had on their quality of life and skin symptom improvement. Each patient also had their Dermatology Life Quality Index (DLQI) score assessed. Results: Out of the 29 patients who responded to the study, 22 had melasma and 7 had post-inflammatory hyperpigmentation from acne. 21 subjects felt that the cream made either a marked or moderate improvement on their quality of life and 23 subjects felt that the cream made either a marked or moderate improvement on their skin symptoms. Conclusion: Patients reported improvement in both hyperpigmentation and quality of life, suggesting a high level of satisfaction with treatment. The long shelf life of the product may also promote compliance and reduce health-care costs.
文摘目的:观察外用3%氨甲环酸精华液治疗黄褐斑的疗效及不良反应。方法:将2021年6月-2021年12月在湘雅医院皮肤科就诊的50例黄褐斑患者按随机数字表法分为两组,实验组外用3%仙瑟氨甲环酸精华液+保湿霜,每日2次;对照组仅外用同种保湿霜,每日2次。每4周回访1次,试验周期为8周,治疗8周停止治疗,随访至12周。回访时依据黄褐斑面积及严重程度评分(Melasma area severity index,MASI)评估疗效,并根据VISIA图评估实验组患者面部红斑改善程度。治疗12周回访时评估复发率、医生及患者满意率并记录不良反应。结果:治疗后4周、8周、12周,实验组的平均MASI均低于对照组,差异具有统计学意义(P<0.05),且实验组患者面部红斑改善情况均优于对照组。随着治疗时间的延长,实验组MASI逐步下降(P<0.05),患者面部红斑改善率逐渐升高。治疗12周回访时医生满意率为88%,患者满意率为92%。结论:外用氨甲环酸治疗黄褐斑疗效肯定,但是对于不同类型的黄褐斑,在起效时间、复发上可能存在不同。配方合理的复合制剂可能是氨甲环酸外用制剂的进一步研究方向。
文摘目的:探讨光子嫩肤仪联合调Q激光治疗黄褐斑的近远期疗效。方法:选取2018年1月-2020年1月笔者科室确诊的118例女性黄褐斑患者,采用简单随机分组法分为观察组和对照组,每组59例。对照组采用调Q激光治疗,每月1次,共治疗6个月;观察组在对照组基础上联合光子嫩肤仪治疗,其中光子嫩肤使用频率为每2个月1次。对比两组患者的疗效,采用SOFT5.5皮肤检测仪对治疗前后皮肤性质进行检测,采用VISIA皮肤分析仪评估棕色斑特征计数,计算其下降率;对比治疗前后患者面部黄褐斑皮损面积与严重程度指数(Melasma area severity index,MASI)评分,记录两组治疗期间面部潮红、轻度水肿、灼痛感等不良反应发生情况;随访12个月,记录两组患者治疗后6个月、9个月、12个月的复发率。结果:治疗后,观察组有效率为96.61%,高于对照组的83.05%(P<0.05);治疗后,观察组色素斑、纹理、皱纹、毛孔及紫质评分均低于对照组(P<0.05);且观察组皮肤水分、弹性评分高于对照组,pH值、油脂评分低于对照组(P<0.05);治疗后,观察组棕色斑计数下降率显著高于对照组,观察组MASI评分显著低于对照组,差异均有统计学意义(P<0.05);治疗期间,两组不良反应发生率比较差异无统计学意义(P>0.05);随访12个月发现,观察组复发率显著低于对照组,差异有统计学意义(P<0.05)。结论:光子嫩肤仪联合调Q激光治疗黄褐斑疗效显著,皮损改善明显,复发率低,值得临床推广应用。
